To the full analysis
Veracyte stock: growth
VCYTVeracyte reported $517.15M in revenue for fiscal 2025, up 16% on the prior year, up 34.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
45.8%
per year from 2011 to 2025, per share 29%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | 34.5% | 26.4% | 45.8% |
| Revenue per share | 24.4% | 13.2% | 29.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $2.65M | −$14.45M | −$13.8M |
| 2012 | $11.63M | −$18.65M | −$8.63M |
| 2013 | $21.88M | −$25.58M | −$20.49M |
| 2014 | $38.19M | −$29.37M | −$29.66M |
| 2015 | $49.5M | −$33.7M | −$33.13M |
| 2016 | $65.09M | −$31.36M | −$32.19M |
| 2017 | $71.95M | −$31M | −$25.67M |
| 2018 | $92.01M | −$23M | −$15.4M |
| 2019 | $120.37M | −$12.6M | −$5.99M |
| 2020 | $117.48M | −$34.91M | −$12.55M |
| 2021 | $219.51M | −$75.56M | −$37M |
| 2022 | $296.54M | −$36.56M | −$1.01M |
| 2023 | $361.05M | −$74.4M | $34.26M |
| 2024 | $445.76M | $24.14M | $63.81M |
| 2025 | $517.15M | $66.35M | $126.63M |
Revenue by segment
How Veracyte, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Testing95%
- Product3%
- Biopharmaceutical And Other2%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Testing | $250.54M | $326.54M | $418.96M | $493.15M | 95.4% |
| Product | $12.63M | $15.59M | $13.65M | $14.33M | 2.8% |
| Biopharmaceutical And Other | $33.36M | $18.92M | $13.15M | $9.66M | 1.9% |
| Total revenue | $296.54M | $361.05M | $445.76M | $517.15M | 100% |
Revenue by region
Where Veracyte, Inc. generates its revenue.
- United States96%
- Outside the US4%
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| United States | $109.61M | $200.98M | $262.92M | $334.53M | $423.54M | $496.6M | 96% |
| Outside the US | $7.87M | $18.53M | $33.61M | $26.53M | $22.23M | $20.55M | 4% |
| Total revenue | $117.48M | $219.51M | $296.54M | $361.05M | $445.76M | $517.15M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Feb 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.